



US007214787B1

(12) **United States Patent**
Smith et al.

(10) **Patent No.:** US 7,214,787 B1
(45) **Date of Patent:** *May 8, 2007

(54) **RECOMBINANT VACCINE AGAINST BOTULINUM NEUROTOXIN**

(75) Inventors: **Leonard A. Smith**, Clarksburg, MD (US); **Michael P. Byrne**, New Market, MD (US); **John L. Middlebrook**, Middletown, MD (US); **Hugh Lapenotiere**, Charlestown, WV (US); **Michael A. Clayton**, Mt. Airy, MD (US); **Douglas R. Brown**, Gaithersburg, MD (US)

(73) Assignee: **United States of America as Represented by the Secretary of the Army**, Washington, DC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: 09/611,419

(22) Filed: Jul. 6, 2000

Related U.S. Application Data

(63) Continuation of application No. PCT/US00/12890, filed on May 12, 2000, and a continuation-in-part of application No. 08/123,975, filed on Sep. 21, 1993, now abandoned.

(60) Provisional application No. 60/146,192, filed on Jul. 29, 1999, provisional application No. 60/133,873, filed on May 12, 1999, provisional application No. 60/133,869, filed on May 12, 1999, provisional application No. 60/133,868, filed on May 12, 1999, provisional application No. 60/133,867, filed on May 12, 1999, provisional application No. 60/133,866, filed on May 12, 1999, provisional application No. 60/133,865, filed on May 12, 1999.

(51) **Int. Cl.**

C07H 21/04 (2006.01)

(52) **U.S. Cl.** 536/23.7; 536/23.1; 514/44; 435/71.1; 435/71.2; 435/69.1

(58) **Field of Classification Search** 514/44; 536/23.1, 23.7, 23.51, 23.4, 24.1; 435/69.1, 435/6, 252.3, 69.7, 320.1, 252.33, 71.1; 424/164.1, 424/164.7, 85.8; 530/350, 825

See application file for complete search history.

(56) **References Cited****U.S. PATENT DOCUMENTS**

- | | | | | |
|----------------|---------|-------------|-------|-----------|
| 4,664,911 A * | 5/1987 | Uhr et al. | | 424/182.1 |
| 5,196,193 A * | 3/1993 | Carroll | | 424/172.1 |
| 5,601,823 A | 2/1997 | Williams | | |
| 5,736,139 A * | 4/1998 | Kink et al. | | 424/164.1 |
| 5,919,665 A * | 7/1999 | Williams | | 435/71.1 |
| 5,965,406 A * | 10/1999 | Murphy | | 435/69.7 |
| 6,290,960 B1 * | 9/2001 | Kink et al. | | 424/164.1 |
| 6,348,450 B1 * | 2/2002 | Tang et al. | | 514/44 |
| 6,495,143 B2 * | 12/2002 | Lee et al. | | 424/199.1 |

6,632,440 B1 * 10/2003 Quinn et al. 424/239.1

FOREIGN PATENT DOCUMENTS

EP	0639081	* 11/1993
WO	91/13090	* 9/1991
WO	9715394	5/1998
WO	0012890	11/2000

OTHER PUBLICATIONS

Clayton et al, Infection and Immunity, vol. 63(7), pp. 2738-2742, 1995.*

Thompson, DE et al, Eur. J. Biochemistry, vol. 189(1), pp. 73-81, 1990.*

Halpern, J. L. et al, Journal of Biological Chemistry, vol. 268(15), pp. 11186-11192, May 25, 1993.*

Binz, T et al, Journal of Biological Chemistry, vol. 265, pp. 9153-9158, 1990.*

Clayton, MA et al, Infection and Immunity, vol. 63(7), pp. 2738-2742, Jul. 1995, Protective Vaccination with a Recombinant Fragment of *Clostridium botulinum* neurotoxin serotype A expressed from a synthetic gene in *Escherichia coli*.*

Szabo, EA et al, Applied and Environmental Microbiology, vol. 59(9), Sep. 1993, pp. 3011-3020, Detection of the genes encoding Botulinum neurotoxin types A to E. by the polymerase chain reaction.*

Promega pSP73 Vector sequence and product map.*

Thompson, DE et al, 1990, European J. Biochem, vol. 189, pp. 73-81.*

Ledoux, DN et al, Toxicon, vol. 33(9), pagtes 1095-1104, 1994 (best copy).*

LaPenotiere, HP et al, Presentation at the International Conference on Botulinum, Tetanus, Neurotoxins: Neurotransmission and Biomedical Aspects, May 11-13, 1992, Madison, Wisconsin, also found in Botulinum and Tetanus Neurotoxins, pp. 463-465 Development of a Molecular Engineered vaccine for C. Botulinum Neurotoxins, Plenum Press, New York, 1993.*

New England Biolab product description for pMAL System, product No. #800.*

Swiss Prot Accession No. P10845, botulinum neurotoxin type A.*

Dertzbaugh, M.T. et al, Vaccine, Nov. 1996, vol. 14(16), apges 1538-1544, Mapping of protective and cross-reactive domains of type A neurotoxin of *Clostridium botulinum*.*

Kurazono, H et al, Journal of Biological Chemistry, Jul. 25, 1992, vol. 267(21), pates 14721-14729.*

LaPenotiere, Hugh F et al, Toxicon, vol. 33(10), pp. 1383-1386, Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen, 1993.*

(Continued)

Primary Examiner—Mark Navarro

Assistant Examiner—Ginny Allen Portner

(74) *Attorney, Agent, or Firm*—Elizabeth Arwine

(57)

ABSTRACT

This invention is directed to preparation and expression of synthetic genes encoding polypeptides containing protective epitopes of botulinum neurotoxin (BoNT). The invention is also directed to production of immunogenic peptides encoded by the synthetic genes, as well as recovery and purification of the immunogenic peptides from recombinant organisms. The invention is also directed to methods of vaccination against botulism using the expressed peptides.